bioRxivBiochemistry
Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations
R. M. Counago, C. K. Allerston, P. Savitsky, H. Azevedo, P. H. Godoi, C. I. Wells, A. Mascarello, F. H. de Souza Gama, K. B. Massirer, W. J. Zuercher, C. R. W. Guimaraes, O. Gileadi
Abstract
The human genome encodes two active Vaccinia-related protein kinases (VRK), VRK1 and VRK2. These proteins have been implicated in a number of cellular processes and linked to a variety of tumors. However, understanding the cellular role of VRKs and establishing their potential use as targets for therapeutic intervention has been limited by the lack of tool compounds that can specifically modulate the activity of these kinases in cells. Here we identified BI-D1870, a dihydropteridine inhibitor of RSK kinases, as a promising starting point for the development of chemical probes targeting the active VRKs. We solved co-crystal structures of both VRK1 and VRK2 bound to BI-D1870 and of VRK1 bound to two broad-spectrum inhibitors. These structures revealed that both VRKs can adopt a P-loop folded conformation, which is stabilized by different mechanisms on each protein. Based on these structures, we suggest modifications to the dihydropteridine scaffold that can be explored to produce potent and specific inhibitors towards VRK1 and VRK2.
- organism: human
- assay: protein structure
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation
Emily Jane Stadnicki, Hannes Ludewig, … Niels Bradshaw·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 31, 2024
- Conformation Selection by ATP-competitive Inhibitors and Allosteric Communication in ERK2
J. W. Anderson, D. Vaisar, … N. G. Ahn·bioRxiv·Sep 12, 2023
- Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2
Nicolai D. Raig, Katherine J. Surridge, … Stefan Knapp·Science AdvancesPeer-reviewed·Jun 6, 2025
- Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2
L. M. Pegram, J. C. Liddle, … N. G. Ahn·bioRxiv·May 16, 2019
- Results of a large scale study of the binding of 50 type IIinhibitors to 348 kinases: The role of protein reorganization
Vardan H. Vardanyan, Allan Haldane, … Ronald M. Levy·Journal of Medicinal ChemistryPeer-reviewed·Apr 9, 2026
- Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
S. H. Schmidt, J.-H. Weng, … S. S. Taylor·bioRxiv·Jul 13, 2020